Early approval for two lipid-based drugs.
Baker
R
R
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000188:drug therapy*; D000666:Amphotericin B / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001228:Aspergillosis / Q000150:complications / Q000188:drug therapy*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D004337:Drug Carriers; D006801:Humans; D008081:Liposomes; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology; D014481:United States; D014486:United States Food and Drug Administration
D000935:Antifungal Agents; D000970:Antineoplastic Agents; D004337:Drug Carriers; D008081:Liposomes; D000666:Amphotericin B; D004317:Doxorubicin